Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG and G-BA. The areas of disagreement included ACT selection, definition of subgroups and patient-relevant endpoints, and classification and balancing of adverse events. </AbstractSection> Copyright The Author(s) 2014

MoreLess

Year of publication:	2014
Authors:	Ruof, Jörg ; Schwartz, Friedrich ; Schulenburg, J.-Matthias ; Dintsios, Charalabos-Markos
Published in:	The European Journal of Health Economics. - Springer. - Vol. 15.2014, 6, p. 577-589
Publisher:	Springer
Subject:	Health care reform \| (Early) benefit assessment \| Appropriate comparative therapy \| Market access \| AMNOG

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10010993901